首页> 美国卫生研究院文献>other >Stem and progenitor cell-based therapy of the central nervous system: Hopes hype and wishful thinking
【2h】

Stem and progenitor cell-based therapy of the central nervous system: Hopes hype and wishful thinking

机译:基于干细胞和祖细胞的中枢神经系统疗法:希望炒作和一厢情愿

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A variety of neurological disorders are attractive targets for stem and progenitor cell-based therapy. Yet many conditions are not, whether by virtue of an inhospitable disease environment, poorly understood pathophysiology, or poor alignment of donor cell capabilities with patient needs. Moreover, some disorders may be medically feasible targets, but are not practicable, in light of already available treatments, poor risk-benefit and cost-benefit profiles, or resource limitations. This Perspective seeks to define those neurological conditions most appropriate for cell replacement therapy, by considering its potential efficacy and clinical feasibility in those disorders, as well as potential impediments to its application.
机译:多种神经系统疾病是基于干细胞和祖细胞治疗的有吸引力的靶标。然而,无论是由于病情恶劣的疾病环境,对病理生理的了解不充分,还是供体细胞功能与患者需求的不良结合,都没有许多条件。而且,鉴于已经可用的治疗方法,不良的风险效益和成本效益概况或资源限制,某些疾病可能是医学上可行的目标,但不切实际。该观点旨在通过考虑其在那些疾病中的潜在功效和临床可行性,以及对其应用的潜在障碍,来确定最适合细胞替代治疗的神经系统疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号